Is AVAH a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on State Medicaid rate increases versus caregiver wages, with revenue (ttm) at ~$2.6B through Q2 2026 (Q2 up ~13.7% year over year). The bear case rests on payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous. Analysts covering it are spread from $13.00 to $16.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $13.00, -0.9% from the $13.12 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

State Medicaid rate increases versus caregiver wages. Private duty revenue rate rose ~5.7% year over year in the first quarter of 2026, driven by reimbursement increases from various state Medicaid programs and managed Medicaid payers. The most optimistic analyst target on AVAH is $16.00, +22.0% from the $13.12 price. That figure is only reachable if this thesis works close to its best case.

Payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous. Leverage magnifies that, since net debt near ~$1.3 billion at the end of the first quarter (before the cash-funded Family First purchase) sits at roughly four times guided adjusted EBITDA against only ~$240 million of book equity; after the acquisition, net debt was about $1.4 billion at July 4, 2026 (~$1.51 billion of debt against ~$109 million of cash). Caregiver supply is the operating constraint, and wage inflation running ahead of rate increases compresses the spread quickly, as the ~8.1% private duty cost rate increase in the first quarter showed. Aveanna has been responding to Department of Justice matters since October 2019, including antitrust grand jury subpoenas covering nurse wages, reimbursement rates and hiring in certain markets, and a 2023 civil investigative demand regarding its Comfort Care Hospice subsidiary, both of which the company says it cannot predict the outcome of. Finally, ~$1.12 billion of goodwill on ~$2.02 billion of assets means an impairment cycle would take book equity negative again, as it was as recently as 2024. The stock's 54% gain in 2026 also raises the bar: with options implied volatility rising ahead of the November 5 report, a miss on the spread or guidance could move the shares sharply. The most pessimistic published target is $13.00, -0.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

Home-based care provider across 39 states, led by private duty nursing for medically complex children, plus home health, hospice and enteral nutrition.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (State Medicaid rate increases versus caregiver wages) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It delivers healthcare in the home rather than in facilities, across 39 states. The bulk of the business is private duty skilled nursing for medically complex children, often many hours per day over years, plus pediatric therapy, school nursing and personal care. Smaller segments provide Medicare-funded home health and hospice to elderly patients and deliver enteral nutrition products.

Government programs, overwhelmingly. In the first quarter of 2026, ~59.2% of revenue came from Medicaid managed care organizations and ~21.8% directly from state Medicaid programs, with Medicare at ~9.9% and commercial insurers at ~8.9%. Self-pay was ~0.2%. That means state legislatures and managed care plans, not patients, set the price of nearly everything Aveanna sells.

Yes on both a GAAP and adjusted basis recently. First-quarter 2026 net income was ~$41.7 million (~$0.19 per diluted share) on ~$647.9 million of revenue, versus ~$5.2 million a year earlier, and adjusted EBITDA was ~$84.4 million. Fiscal 2025 GAAP net income of ~$225.0 million was inflated by a non-cash deferred tax benefit, since pre-tax income that year was only ~$106.9 million. Over the twelve months to July 4, 2026, net income was about $275 million on roughly $2.6 billion of revenue, and second-quarter EPS of $0.22 beat the $0.17 consensus.